You are here: Homepage


Welcome to the official website of the FOCUS project, a European collaborative research project supported by the European Commission.  

FOCUS stands for Fixed Dose Combination Drug for Secondary cardiovascular Prevention and aims at testing a Fixed-Dose-Combination (FDC) pill for cardiovascular prevention and treatment in populations with diverse socio-economic characteristics. The recommendations drafted by FOCUS for improved use of medication in patients with ischemic heart disease will contribute to a more rapid adoption of FDC medication for the treatment of chronic diseases in medical practice, and to making medication more available and affordable for large numbers of patients in developed and developing countries.

FOCUS is a 4.7-million Euros European project of the Seventh Framework Programme (FP7), partly funded by the European Commission and coordinated by Ginés Sanz from the National Centre for Cardiovascular Research (CNIC by its Spanish acronym). Consortium Members brings together research institutes, clinicians, pharmaceutical company, SMEs and scientific organisations across Europe and Latin America that will study the FDC concept in a variety of social and economic settings to investigate the effect of an FDC pill on patients’ adherence and on the improved efficiency of secondary prevention.

Dr. Valentín Fuster
General Director of Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Principal Investigator for FOCUS

Centro Nacional de Investigaciones Cardiovasculares (CNIC)
Istituto di Richerche Farmacologiche Mario Negri (IRFMN)
Instituto DAMIC (DAMIC)
Fundació Clínic per a la recerca Biomèdica (FCRB)
Federación Argentina de Cardiología (FAC)
World Heart Federation (WHF)
Instituto de Salud Carlos III (ISCIII